6,834 Shares in Gilead Sciences, Inc. $GILD Purchased by Virtus Family Office LLC

Virtus Family Office LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,834 shares of the biopharmaceutical company’s stock, valued at approximately $839,000.

A number of other large investors have also added to or reduced their stakes in the stock. Alpha Cubed Investments LLC increased its holdings in Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares during the last quarter. Personal CFO Solutions LLC increased its holdings in Gilead Sciences by 1.7% during the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares during the last quarter. Moss Adams Wealth Advisors LLC increased its holdings in Gilead Sciences by 1.7% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after buying an additional 76 shares during the last quarter. Valued Wealth Advisors LLC increased its holdings in Gilead Sciences by 12.5% during the fourth quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 79 shares during the last quarter. Finally, SOA Wealth Advisors LLC. increased its holdings in Gilead Sciences by 8.7% during the fourth quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 81 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q1 results beat expectations: Gilead reported $2.03 EPS and $6.96B revenue, above consensus, with core products (notably Biktarvy) driving 4.4% year-over-year sales growth. Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Gilead raised its 2026 sales outlook (reiterating solid top-line momentum), which partially offsets concerns about near-term profitability. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
• Neutral Sentiment: Board/shareholder matters and communications: shareholders approved board pay plans at the 2026 meeting; the earnings call transcript and slide deck are available for deeper investor review. Listen to Conference Call
• Neutral Sentiment: Dividend declared: Gilead announced a quarterly dividend of $0.82/share (record June 15; payable June 29), supporting income?oriented holders. (Company release)
• Negative Sentiment: Massive acquisition-related charges: management flagged roughly $11.5B of acquisition charges and associated financing costs that drove FY?2026 adjusted EPS guidance down to an expected loss of $0.65–$1.05 per share (vs. prior positive guidance and analyst expectations). That guidance hit is the primary reason the stock is trading lower. Gilead Sciences (GILD) Stock Drops Despite Q1 Beat on Massive Acquisition Charges
• Negative Sentiment: Market reaction and analyst focus: coverage highlights that the firm now expects an adjusted loss due to acquired R&D and transaction costs, prompting some analysts to re-evaluate near-term earnings models and risk premiums. Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $134.06 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $166.40 billion, a PE ratio of 19.80, a P/E/G ratio of 1.80 and a beta of 0.31. Gilead Sciences, Inc. has a twelve month low of $95.29 and a twelve month high of $157.29. The company has a 50-day moving average price of $139.59 and a two-hundred day moving average price of $132.87.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the business earned $1.81 earnings per share. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 8.62 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares in the company, valued at approximately $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 63,000 shares of company stock worth $9,238,250. 0.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research report on Monday, February 23rd. Argus increased their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. BMO Capital Markets increased their target price on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Finally, Leerink Partners increased their target price on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $157.35.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.